Birchview Capital
Latest statistics and disclosures from Birchview Capital's latest quarterly 13F-HR filing:
- Top 5 stock holdings are KLAC, BMY, CMPX, LRCX, STOK, and represent 39.93% of Birchview Capital's stock portfolio.
- Added to shares of these 10 stocks: RLMD, OCUL, CLDX, CMPS, ENGN, NTLA, ZBIO, PACB, QURE, BIIB.
- Started 17 new stock positions in RGNX, BIIB, QNRX, RLMD, OCUL, GRCE, ENGN, LPCN, CMPS, Karyopharm Therapeutics. RCUS, CLDX, ZBIO, RCKT, VRDN, KYNB, IDYA.
- Reduced shares in these 10 stocks: , KLAC, PTGX, IMNM, CSTL, STOK, MASI, TXG, LRCX, VTYX.
- Sold out of its positions in ATEC, ALMS, FOLD, ILMN, INBX, LQDA, MASI, RAPT, TXG, TMCI. VTYX, Biohaven Pharmaceutical Holding.
- Birchview Capital was a net seller of stock by $-1.6M.
- Birchview Capital has $176M in assets under management (AUM), dropping by 2.85%.
- Central Index Key (CIK): 0001618205
Tip: Access up to 7 years of quarterly data
Positions held by Birchview Capital consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Birchview Capital
Birchview Capital holds 73 positions in its portfolio as reported in the March 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Kla Corporation Com New (KLAC) | 16.7 | $29M | -9% | 20k | 1472.41 |
|
| Bristol Myers Squibb (BMY) | 10.6 | $19M | 306k | 60.65 |
|
|
| Compass Therapeutics (CMPX) | 4.4 | $7.8M | -7% | 1.5M | 5.29 |
|
| Lam Research Corporation Com New (LRCX) | 4.4 | $7.7M | -10% | 36k | 213.66 |
|
| Stoke Therapeutics (STOK) | 3.9 | $6.8M | -19% | 210k | 32.56 |
|
| Encana Corporation (OVV) | 3.6 | $6.4M | 108k | 59.36 |
|
|
| Intellia Therapeutics (NTLA) | 3.3 | $5.7M | +41% | 445k | 12.82 |
|
| Structure Therapeutics Spons Adr (GPCR) | 2.7 | $4.8M | +11% | 100k | 48.20 |
|
| Solid Biosciences Com New (SLDB) | 2.6 | $4.5M | -11% | 626k | 7.20 |
|
| Prothena Corp SHS (PRTA) | 2.5 | $4.4M | 449k | 9.72 |
|
|
| Biodesix | 2.4 | $4.2M | 287k | 14.50 |
|
|
| ACADIA Pharmaceuticals (ACAD) | 2.2 | $3.8M | 171k | 22.26 |
|
|
| Protagonist Therapeutics (PTGX) | 2.1 | $3.7M | -36% | 35k | 105.40 |
|
| Neurocrine Biosciences (NBIX) | 2.0 | $3.6M | 27k | 131.74 |
|
|
| Olema Pharmaceuticals (OLMA) | 1.9 | $3.3M | -18% | 219k | 14.91 |
|
| Relmada Therapeutics (RLMD) | 1.6 | $2.8M | NEW | 409k | 6.96 |
|
| Ocular Therapeutix (OCUL) | 1.5 | $2.7M | NEW | 320k | 8.47 |
|
| United Therapeutics Corporation (UTHR) | 1.5 | $2.7M | +50% | 4.5k | 592.98 |
|
| Nektar Therapeutics (NKTR) | 1.3 | $2.2M | 31k | 71.95 |
|
|
| Celldex Therapeutics Com New (CLDX) | 1.3 | $2.2M | NEW | 70k | 31.72 |
|
| Novocure Ord Shs (NVCR) | 1.3 | $2.2M | +33% | 202k | 10.90 |
|
| EQT Corporation (EQT) | 1.3 | $2.2M | 35k | 63.64 |
|
|
| Phathom Pharmaceuticals (PHAT) | 1.2 | $2.2M | 195k | 11.11 |
|
|
| Bicycle Therapeutics Sponsored Ads (BCYC) | 1.2 | $2.2M | 464k | 4.64 |
|
|
| Compass Pathways Sponsored Ads (CMPS) | 1.2 | $2.1M | NEW | 375k | 5.53 |
|
| Pacific Biosciences of California (PACB) | 1.1 | $2.0M | +200% | 1.5M | 1.32 |
|
| Cytokinetics (CYTK) | 1.1 | $2.0M | 30k | 65.91 |
|
|
| Corcept Therapeutics Incorporated (CORT) | 1.1 | $1.9M | -29% | 47k | 40.31 |
|
| Vera Therapeutics Cl A (VERA) | 1.0 | $1.8M | 44k | 40.23 |
|
|
| Alkermes SHS (ALKS) | 1.0 | $1.8M | 50k | 35.36 |
|
|
| Engene Holdings (ENGN) | 1.0 | $1.7M | NEW | 250k | 6.81 |
|
| Uniqure Nv SHS (QURE) | 0.9 | $1.6M | +227% | 101k | 16.35 |
|
| Zenas Biopharma (ZBIO) | 0.8 | $1.4M | NEW | 70k | 19.55 |
|
| Quidel Corporation | 0.8 | $1.4M | +13% | 83k | 16.43 |
|
| Foghorn Therapeutics (FHTX) | 0.8 | $1.3M | 282k | 4.78 |
|
|
| Ultragenyx Pharmaceutical (RARE) | 0.7 | $1.3M | 62k | 20.95 |
|
|
| Xenon Pharmaceuticals (XENE) | 0.7 | $1.2M | 21k | 58.15 |
|
|
| Kalvista Pharmaceuticals (KALV) | 0.7 | $1.1M | 57k | 20.13 |
|
|
| Immunome (IMNM) | 0.6 | $1.1M | -61% | 50k | 21.87 |
|
| Freeport-mcmoran Cl-b CL-B (FCX) | 0.6 | $1.1M | 18k | 58.78 |
|
|
| Axsome Therapeutics (AXSM) | 0.6 | $1.0M | 6.0k | 169.02 |
|
|
| Biogen Idec (BIIB) | 0.5 | $917k | NEW | 5.0k | 183.33 |
|
| Lipocine Com New (LPCN) | 0.5 | $893k | NEW | 112k | 7.99 |
|
| Travere Therapeutics (TVTX) | 0.5 | $868k | -32% | 29k | 29.71 |
|
| Harrow Health (HROW) | 0.5 | $846k | -29% | 24k | 35.26 |
|
| Pharvaris N V (PHVS) | 0.5 | $843k | 30k | 28.25 |
|
|
| Verastem Com New (VSTM) | 0.5 | $795k | 150k | 5.30 |
|
|
| Apogee Therapeutics (APGE) | 0.4 | $758k | -43% | 9.0k | 84.17 |
|
| Halozyme Therapeutics (HALO) | 0.4 | $653k | 10k | 64.63 |
|
|
| Bridgebio Pharma (BBIO) | 0.4 | $645k | 8.7k | 74.26 |
|
|
| Apellis Pharmaceuticals (APLS) | 0.3 | $563k | 14k | 40.23 |
|
|
| Ideaya Biosciences (IDYA) | 0.3 | $562k | NEW | 17k | 33.32 |
|
| Arcus Biosciences Incorporated (RCUS) | 0.3 | $559k | NEW | 26k | 21.60 |
|
| Regenxbio Inc equity us cm (RGNX) | 0.3 | $555k | NEW | 66k | 8.38 |
|
| Karyopharm Therapeutics | 0.3 | $468k | NEW | 84k | 5.57 |
|
| Rocket Pharmaceuticals (RCKT) | 0.3 | $455k | NEW | 127k | 3.58 |
|
| Miragen Therapeutics (VRDN) | 0.2 | $393k | NEW | 20k | 19.56 |
|
| Outset Med | 0.2 | $380k | 99k | 3.84 |
|
|
| Pulmonx Corp (LUNG) | 0.2 | $323k | 250k | 1.29 |
|
|
| Castle Biosciences (CSTL) | 0.2 | $317k | -83% | 13k | 24.55 |
|
| Trinity Cap (TRIN) | 0.2 | $294k | 20k | 14.71 |
|
|
| Candel Therapeutics (CADL) | 0.2 | $294k | 60k | 4.90 |
|
|
| Voyager Therapeutics (VYGR) | 0.2 | $289k | 75k | 3.86 |
|
|
| Cullinan Oncology (CGEM) | 0.2 | $284k | 20k | 14.21 |
|
|
| Kayne Anderson Bdc Com Shs (KBDC) | 0.2 | $274k | 20k | 13.72 |
|
|
| Acasti Pharma (GRCE) | 0.1 | $232k | NEW | 50k | 4.63 |
|
| Aziyo Biologics (ELUT) | 0.1 | $173k | -37% | 165k | 1.05 |
|
| Kyntra Bio Com New (KYNB) | 0.1 | $153k | NEW | 23k | 6.78 |
|
| Quoin Pharmaceuticals Sponsored Ads (QNRX) | 0.1 | $132k | NEW | 20k | 6.60 |
|
| Phreesia (PHR) | 0.1 | $120k | -87% | 14k | 8.38 |
|
| Zentalis Pharmaceuticals (ZNTL) | 0.0 | $41k | +2% | 18k | 2.34 |
|
| Docgo (DCGO) | 0.0 | $25k | -20% | 40k | 0.63 |
|
| Gossamer Bio (GOSS) | 0.0 | $6.0k | -86% | 18k | 0.33 |
|
Past Filings by Birchview Capital
SEC 13F filings are viewable for Birchview Capital going back to 2014
- Birchview Capital 2026 Q1 filed May 15, 2026
- Birchview Capital 2025 Q4 filed Feb. 13, 2026
- Birchview Capital 2025 Q3 filed Nov. 13, 2025
- Birchview Capital 2025 Q2 filed Aug. 14, 2025
- Birchview Capital 2023 Q3 amended filed June 30, 2025
- Birchview Capital 2023 Q4 amended filed June 30, 2025
- Birchview Capital 2024 Q1 amended filed June 30, 2025
- Birchview Capital 2024 Q2 amended filed June 30, 2025
- Birchview Capital 2024 Q3 amended filed June 30, 2025
- Birchview Capital 2024 Q4 amended filed June 30, 2025
- Birchview Capital 2025 Q1 filed May 15, 2025
- Birchview Capital 2024 Q4 filed Feb. 14, 2025
- Birchview Capital 2024 Q3 filed Nov. 14, 2024
- Birchview Capital 2024 Q2 filed Aug. 13, 2024
- Birchview Capital 2024 Q1 filed May 14, 2024
- Birchview Capital 2023 Q4 filed Feb. 14, 2024